Literature DB >> 8622626

Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.

E B Haddad1, J Rousell, J C Mak, P J Barnes.   

Abstract

In human embryonic lung fibroblasts, transforming growth factor-beta 1 (TGF-beta 1) induced a time-dependent down-regulation of M2 muscarinic receptor binding sites as measured with the nonselective hydrophilic ligand [3H]N-methylscopolamine (NMS). This down-regulation was slow, with 58% loss of all receptors after 24 hr of treatment. The affinity of [3H]NMS for the remaining sites was unaltered by TGF-beta 1. The loss in [3H]NMS binding was accompanied by reduced adenylyl cyclase activity and functional desensitization of M2 muscarinic receptors. Northern blot analyses showed a 72% decrease in the steady state levels of m2 muscarinic receptor mRNA after 24-hr TGF-beta 1 treatment. Recovery of m2 muscarinic receptor mRNA after TGF-beta 1 treatment was slow, with a half-life of approximately 8 hr. There was no effect of TGF-beta 1 on the m2 muscarinic receptor mRNA half-life measured in the presence of actinomycin D, but the rate of m2 muscarinic receptor gene transcription measured with nuclear run-on assay was reduced by 50%, indicating reduced gene transcription. Cycloheximide (10 micrograms/ml) pretreatment abolished the TGF-beta 1 effect, indicating that de novo protein synthesis was required for receptor downregulation. In summary, we have shown that TGF-beta 1 induced desensitization and down-regulation of M2 muscarinic receptor protein and gene that was mediated through reduction in the rate of m2 receptor gene transcription.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622626

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

Authors:  Michael Roth
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

2.  Metformin prevents airway hyperreactivity in rats with dietary obesity.

Authors:  Gina N Calco; Becky J Proskocil; David B Jacoby; Allison D Fryer; Zhenying Nie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 6.011

Review 3.  Pulmonary fibroblasts, an emerging target for anti-obstructive drugs.

Authors:  Kurt Racké; Susanne Haag; Amit Bahulayan; Mareille Warnken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-13       Impact factor: 3.000

4.  Virus- and interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons.

Authors:  D B Jacoby; H Q Xiao; N H Lee; Y Chan-Li; A D Fryer
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

5.  Aclidinium inhibits human lung fibroblast to myofibroblast transition.

Authors:  Javier Milara; Adela Serrano; Teresa Peiró; Amadeu Gavaldà; Montserrat Miralpeix; Esteban Jesús Morcillo; Julio Cortijo
Journal:  Thorax       Date:  2011-09-28       Impact factor: 9.139

6.  Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M2 receptor dysfunction.

Authors:  Becky J Proskocil; Allison D Fryer; David B Jacoby; Zhenying Nie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-05-19       Impact factor: 6.011

7.  Association of Autoantibodies against M2-Muscarinic Acetylcholine Receptor with Atrial Fibrosis in Atrial Fibrillation Patients.

Authors:  Guiling Ma; Xuejiao Wu; Lijun Zeng; Jiawei Jin; Xingpeng Liu; Jianjun Zhang; Lin Zhang
Journal:  Cardiol Res Pract       Date:  2019-02-04       Impact factor: 1.866

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.